Готові списки джерел за темами / Chemoradiotheraoy

Добірка наукової літератури з теми "Chemoradiotheraoy"

Автор: Grafiati
Опубліковано: 10 грудня 2022
Оновлено: 29 січня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Зміст

Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Chemoradiotheraoy".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Статті в журналах з теми "Chemoradiotheraoy"

1

Rose, Peter G. "Chemoradiotherapy." Drugs 60, no. 6 (December 2000): 1239–44. http://dx.doi.org/10.2165/00003495-200060060-00001.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Chang, Yi-Lin, Ya-Fu Cheng, Hui-Shan Chen, Siao-Chi Wu, Wei-Heng Hung, Heng-Chung Chen, Chang-Lun Huang, Ching-Yuan Cheng, and Bing-Yen Wang. "Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma." PLOS ONE 17, no. 10 (October 13, 2022): e0271338. http://dx.doi.org/10.1371/journal.pone.0271338.

Повний текст джерела
Анотація:
Introduction The purpose of the current study is to compare definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with cT1-3/N0-3 esophageal squamous cell carcinoma in survival. Methods Records from 2008 to 2014 of 4931 patients with clinical T1-3/N0-3 esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or esophagectomy with adjuvant chemoradiotherapy were obtained from the Taiwan Cancer Registry. Univariable and multivariable analyses were performed and propensity score matching was used to minimize the bias. Overall survival was compared between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy, and also in the three different clinical stages. Results Definitive chemoradiotherapy was performed on 4381 patients, and 550 patients received esophagectomy adjuvant chemoradiotherapy. Each group produced 456 patients for comparison after propensity score matching. The 1-year, 2-year, and 3-year overall survival rates for matched patients in with definitive chemoradiotherapy group were 57.18%, 31.92%, and 23.8%. The 1-year, 2-year, and 3-year overall survival rates for matched patients treated in the esophagectomy with adjuvant chemoradiotherapy group were 72.35%, 45.74%, and 34.04%(p<0.0001). In multivariable analysis, treatment modality was an independent prognostic factor. Esophagectomy with adjuvant chemoradiotherapy provided better survival outcome than definitive chemoradiotherapy for patients with clinical stage II/III disease. As for patients with clinical stage I disease, there was no significant survival difference between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy. Conclusions Esophagectomy with adjuvant chemoradiotherapy provided better survival than definitive chemoradiotherapy in clinical II/III esophageal squamous cell carcinoma. However, more data are needed to conduct a convincing conclusion in clinical stage I patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Xu, Guoqiang, Qiaoli Wang, Xingrao Wu, Chunyan Lv, Guilin Zeng, Zhihong Xue, Ruixue Cao, Nan Zhang, Wei Xiong, and Qin Huang. "Comparison of Induction Chemotherapy Plus Concurrent Chemoradiotherapy and Concurrent Chemoradiotherapy Alone in Locally Advanced Nasopharyngeal Carcinoma." Technology in Cancer Research & Treatment 20 (January 1, 2021): 153303382199001. http://dx.doi.org/10.1177/1533033821990017.

Повний текст джерела
Анотація:
Purpose: Induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone are both standard treatment regimens for managing locally advanced nasopharyngeal carcinoma. However, the results of comparisons between them in clinical trials vary. Therefore, we designed this meta-analysis to illustrate their advantages and disadvantages in patients with locally advanced nasopharyngeal carcinoma. Methods: We thoroughly searched the PubMed, EMBASE, and Cochrane Library databases and then merged the effect indicators of hazard ratios and risk ratios using RevMan 5.1. Results: Seven randomized controlled trials totaling 2,319 patients were included in our research. The synthesized results showed that induction chemotherapy plus concurrent chemoradiotherapy improved overall survival (HR = 0.75, 95% CI: 0.63-0.89, P = 0.001), progression-free survival (HR = 0.69, 95% CI: 0.60-0.80, P < 0.001), distant metastasis-free survival (HR = 0.65, 95% CI: 0.53-0.80, P < 0.001) and locoregional recurrence-free survival (HR = 0.68 95%, CI: 0.54-0.86, P = 0.001) versus concurrent chemoradiotherapy alone. It also increased the risk of anemia, thrombocytopenia, and neutropenia during concurrent chemoradiotherapy. However, the incidence of leukopenia and mucositis was similar in induction chemotherapy and induction chemotherapy plus concurrent chemoradiotherapy. Furthermore, the subgroup analysis showed better survival outcomes with induction chemotherapy plus concurrent chemoradiotherapy than with concurrent chemoradiotherapy alone in the triweekly cisplatin subgroup (all P < 0.01), whereas induction chemotherapy plus concurrent chemoradiotherapy could only improve progression-free survival and locoregional recurrence-free survival in the weekly cisplatin subgroup (HR = 0.78, P = 0.02; and HR = 0.66, P = 0.03, respectively). Conclusions: Induction chemotherapy plus concurrent chemoradiotherapy improved survival outcomes in patients with locally advanced nasopharyngeal carcinoma versus concurrent chemoradiotherapy. For the weekly cisplatin regimen subgroup, it did not improve remote control or overall survival versus concurrent chemoradiotherapy alone, warranting further clarification.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Stahl, Michael, and Wilfried Budach. "Definitive chemoradiotherapy." Journal of Thoracic Disease 9, S8 (July 2017): S792—S798. http://dx.doi.org/10.21037/jtd.2017.05.05.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Mornex, F., N. Girard, and V. Wautot. "18IN CHEMORADIOTHERAPY." Lung Cancer 64 (May 2009): S10. http://dx.doi.org/10.1016/s0169-5002(09)70141-2.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Aref, A. "Concomitant chemoradiotherapy." Journal of Clinical Oncology 8, no. 11 (November 1990): 1928–30. http://dx.doi.org/10.1200/jco.1990.8.11.1928.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Vokes, Everett E., and Ralph R. Weichselbaum. "Concomitant Chemoradiotherapy." Journal of Clinical Oncology 8, no. 8 (August 1990): 1447. http://dx.doi.org/10.1200/jco.1990.8.8.1447.

Повний текст джерела
Анотація:
The title of Table 4 in the review article "Concomitant Chemoradiotherapy: Rationale and Clinical Experience in Patients With Solid Tumors" by Vokes and Weichselbaum published in the May 1990 issue (J Clin Oncol 8:911–934, 1990) was incorrect. It should have read "Table 4: Selected Randomized Trials in Head and Neck Cancer."
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Vokes, Everett E., David M. Brizel, and Theodore S. Lawrence. "Concomitant Chemoradiotherapy." Journal of Clinical Oncology 25, no. 26 (September 10, 2007): 4031–32. http://dx.doi.org/10.1200/jco.2007.13.8073.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

West, Malcolm A., Zachos Anastasiou, Gareth Ambler, Lisa Loughney, Michael G. Mythen, Thomas Owen, Gerard Danjoux, et al. "The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study." NIHR Open Research 1 (June 16, 2021): 1. http://dx.doi.org/10.3310/nihropenres.13217.1.

Повний текст джерела
Анотація:
Background: Neoadjuvant cancer treatment is associated with improved survival following major oesophagogastric cancer surgery. The impact of neoadjuvant chemo/chemoradiotherapy on physical fitness and operative outcomes is however unclear. This study aims to investigate the impact of neoadjuvant chemo/chemoradiotherapy on fitness and post-operative mortality. Methods: Patients with oesophagogastric cancer scheduled for chemo/chemoradiotherapy and surgery were recruited to a prospective, blinded, multi-centre, observational cohort study. Primary outcomes were changes in fitness with chemo/chemoradiotherapy, measured using cardiopulmonary exercise testing and its association with mortality one-year after surgery. Patients were followed up for re-admission at 30-days, in-hospital morbidity and quality of life (exploratory outcomes). Results: In total, 384 patients were screened, 217 met the inclusion criteria, 160 consented and 159 were included (72% male, mean age 65 years). A total of 132 patients (83%) underwent chemo/chemoradiotherapy, 109 (71%) underwent chemo/chemoradiotherapy and two exercise tests, 100 (63%) completed surgery and follow-up. A significant decline in oxygen uptake at anaerobic threshold and oxygen uptake peak was observed following chemo/chemoradiotherapy: -1.25ml.kg-1.min-1 (-1.80 to -0.69) and -3.02ml.kg-1.min-1 (-3.85 to -2.20); p<0.0001). Baseline chemo/chemoradiotherapy anaerobic threshold and peak were associated with one-year mortality (HR=0.72, 95%CI 0.59 to 0.88; p=0.001 and HR=0.85, 0.76 to 0.95; p=0.005). The change in physical fitness was not associated with one-year mortality. Conclusion: Chemo/chemoradiotherapy prior to oesophagogastric cancer surgery reduced physical fitness. Lower baseline fitness was associated with reduced overall survival at one-year. Careful consideration of fitness prior to chemo/chemoradiotherapy and surgery is urgently needed.
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Terada, Hoshino, Yuzo Shimode, Madoka Furukawa, Yuichiro Sato, and Nobuhiro Hanai. "The Utility of Ultrasonography in the Diagnosis of Cervical Lymph Nodes after Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma." Medicina 57, no. 5 (April 23, 2021): 407. http://dx.doi.org/10.3390/medicina57050407.

Повний текст джерела
Анотація:
Background and Objectives: There is evidence or consensus on the use of 18F-2-fluorodeoxyglucose-positron emission tomography with computed tomography (PET-CT) in evaluating the effects of treatment at 12 weeks after chemoradiotherapy for head and neck squamous cell carcinoma with cervical lymph node metastasis. However, the use of imaging to evaluate the effects of treatment within 12 weeks after chemoradiotherapy is controversial. The aim of this study was to evaluate the usefulness of ultrasonography in the diagnosis of lymph nodes metastasis after chemoradiotherapy according to the criteria of the “Evaluation of the effects of treatment on metastatic cervical lymph nodes using ultrasonography”, which evaluated lymph nodes metastasis based on size change and presence of degeneration. Materials and methods: This prospective study included 34 head and neck squamous cell carcinoma patients with cervical lymph nodes metastasis. Thirty-two patients who completed treatment were analyzed. Ultrasonography was performed at 4 and 8 weeks after chemoradiotherapy and we judged whether a favorable prognosis could be expected or whether additional treatments should be considered. Ultrasonography and PET-CT were performed at 12 weeks after chemoradiotherapy. Neck dissection was performed if residual disease was suspected based on the PET-CT findings. Results: The accuracy and negative predictive value of ultrasonography were 81.3% and 96.3%, respectively. According to the Ultrasonography findings, the size of lymph nodes metastasis after chemoradiotherapy was significantly smaller than those before chemoradiotherapy (p < 0.05). The fluid and blood flow of lymph nodes metastasis showed a significantly reduced at 12 weeks after chemoradiotherapy (p < 0.05, p < 0.05, respectively). The echo density significantly changed from low to high echoic density after chemoradiotherapy (p < 0.05). Conclusions: Ultrasonography was useful for evaluating cervical lymph nodes metastasis after chemoradiotherapy for head and neck squamous cell carcinoma.
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Дисертації з теми "Chemoradiotheraoy"

1

Meerten, Esther van. "Chemotherapy and Chemoradiotherapy Studies in Oesophageal Cancer." [S.l.] : Rotterdam : [The Author] ; Erasmus University [Host], 2008. http://hdl.handle.net/1765/13209.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Witztum, Alon. "Modelling normal tissue toxicity in pancreatic chemoradiotherapy." Thesis, University of Oxford, 2018. http://ora.ox.ac.uk/objects/uuid:52a0b44b-84d4-444e-9f2a-fdbe0fc29edf.

Повний текст джерела
Анотація:
The relationship between radiation dose and toxicity in pancreatic chemoradiotherapy is not well understood. Clinically, excessive normal tissue toxicity is avoided by placing a constraint on the volume of the organ receiving a dose above a threshold. Dose-volume constraints lack spatial information which may be important in determining normal tissue response. Spatial dose distribution information can be found in dose-surface maps (DSMs). A dose-surface map is a 2-dimensional virtual unwrapping of the surface dose of on organ. Due to the complex geometry of the duodenum, previous methods for unwrapping tubular organs for spatial toxicity modelling are insuficient. A geometrically robust method for producing dose-surface maps, specifically for the duodenum, was created in order to characterise the spatial dose distribution. This unwrapping methodology was shown to be generalisable to simple organs such as the stomach, and extendable to more complex organs such as the bronchial tree. A graphical user interface to create dose-surface maps from organs in commercial treatment planning systems was also demonstrated. Duodenal and stomach dose-surface maps were created for patients from two pancreatic chemoradiotherapy trials, ARCII and SCALOP, treating locally-advanced pancreatic cancer (LAPC). New spatial features were extracted from dose-surface maps and their correlation with upper-gastrointestinal toxicity quantified and compared to traditional dose-volume metrics. The predictive power of some of these new metrics were found to be superior to dose-volume metrics in the stomach, but no significant correlation was found in the duodenum. Duodenal motion throughout treatment occurs both due to respiratory motion and peristalsis. On board imaging using cone-beam CT (CBCT) during individual treatment fractions shows that interfraction variability is non-systematic and cannot be predicted. While abdominal compression is able to restrict some interfraction motion, it is unable to control peristaltic changes. Accumulated duodenal dose-surface maps from these images were created to investigate the differences between the planned and delivered dose.
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Lee, W. M. Anne, and 李詠梅. "Therapeutic benefits of concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B41290677.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Lee, W. M. Anne. "Therapeutic benefits of concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma." Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B41290677.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Alderdice, Matthew. "Personalised medicine in rectal cancer : understanding and predicting response to neoadjuvant chemoradiotherapy." Thesis, Queen's University Belfast, 2017. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.725327.

Повний текст джерела
Анотація:
Around 12-15% of patients with locally advanced rectal cancer (LARC) undergo a pathologically complete response (Tumour Regression Grade 4 - TRG4) to neoadjuvant chemoradiotherapy; the remainder exhibit a spectrum of tumour regression (TRG1-3). Understanding therapy-related genomic alterations may help us better predict response, progression-free and overall survival, and also identify both novel and repurposed treatment strategies based on the underlying biology of the disease. The Northern Ireland Biobank provided 48 formalin fixed paraffin embedded (FFPE) rectal cancer biopsies and matched resections following neoadjuvant therapy (discovery cohort). These were analysed using high-throughput gene expression microarray, DNA mutational profiling and microsatellite instability profiling. Differential gene expression analysis (analysis of variance) was performed contrasting tumour regression grades in both biopsies and resections to identify predictive and therapy related features. Real time PCR was utilised for microarray validation while immunohistochemistry (IHC) was employed to measure CD56+ cell populations in an independent (validation) cohort (n=150). A NK cell-like gene expression signature was observed following long course chemoradiotherapy in a tumour regression-dependent manner. CD56+ NK cel, populations were measured by IHC and found to be significantly higher in TRG3 patients. Furthermore, it was observed that patients positive for CD56 ceils after therapy had a better overall survival (HR=0.282, 95%C,=0.109-0.729, x2=7.854, p=.OO5). In silico drug selection using QUADrATiC analysis identified clinically relevant therapeutic FDA-approved compounds based upon the NK cell-like signature. We demonstrated that identifying an independently validated predictive signature from biopsies for LARC patients treated with LCPCRT was not possible. However, we identified a novel post-therapeutic NK-like transcription signature in patients responding to neoadjuvant chemoradiotherapy. Furthermore, CD56 positive patients had better overall survival. Therefore, harnessing an NK-like response after therapy may improve outcomes for locally advanced rectal cancer patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Shyam, Sunitha. "S-phase Synchronization Promotes Chemoradiotherapy-induced Apoptosis in Prostate Cancer Cell Lines." Kent State University / OhioLINK, 2007. http://rave.ohiolink.edu/etdc/view?acc_num=kent1185835523.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Fujii, Kota. "Association of Chemoradiotherapy With Thoracic Vertebral Fractures in Patients With Esophageal Cancer." Doctoral thesis, Kyoto University, 2021. http://hdl.handle.net/2433/264656.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Chand, Manish. "The prognostic role of extramural venous invasion in post-chemoradiotherapy rectal cancer." Thesis, Imperial College London, 2015. http://hdl.handle.net/10044/1/31467.

Повний текст джерела
Анотація:
Introduction Extramural venous invasion (EMVI) is a poor prognostic factor in rectal cancer. It is detected by magnetic resonance imaging (MRI) and histopathological analysis. Neoadjuvant chemoradiotherapy (CRT) is often given to patients with locally advanced disease however the clinical outcomes of EMVI-positive tumours following such treatment remains unknown. This thesis aimed to investigate the radiological, pathological and molecular changes which occur in EMVI-positive tumours following CRT to determine whether these changes can predict prognosis. Methods Following a systematic review (SR) of EMVI in rectal cancer, a series of studies were conducted. Patients were identified from a prospectively maintained database of primary rectal cancers who were scheduled for CRT followed by curative surgery between 2006 and 2012. Imaging and pathology samples were reviewed and tissue samples were further processed for molecular profiling using micro-RNA analytical techniques. Data were correlated with disease-free survival (DFS), recurrence rate and patterns of relapse. Results SR demonstrated that EMVI is associated with locally advanced tumours, distant disease recurrence and worse overall survival. However there is a variation in technique and definitions which makes interpretation of historical studies problematic. EMVI is an important consideration in the multidisciplinary management of rectal cancer as most clinicians use it to influence treatment decisions. MRI may allow for improved detection rates of EMVI following CRT compared with routine histopathology techniques and it is an independent prognostic factor for recurrence at 3 years. Patients with persistent EMVI following CRT have improved DFS if given adjuvant chemotherapy. Finally, EMVI-positive tumours express specific patterns of microRNA sequences. Conclusion EMVI is a poor prognostic factor following CRT. Patients with evidence of EMVI may be considered for intensive adjuvant chemotherapy and more frequent surveillance for distant disease. Unique molecular signatures may hold the key for future management strategies. These results have led to the development of the MARVEL Study.
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Fujita, Shiro. "Postoperative complications after induction chemoradiotherapy in patients with non-small-cell lung cancer." Kyoto University, 2008. http://hdl.handle.net/2433/135810.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Tohnai, Iwai. "Chemotherapy using Intra-Arterial Infusion for Oral Cancer." Nagoya University School of Medicine, 2006. http://hdl.handle.net/2237/6962.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Більше джерел

Книги з теми "Chemoradiotheraoy"

1

Head and neck cancer recurrence: Evidence-based, multidisciplinary management. Stuttgart: Thieme, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Sullivan, Daniel. Chemoradiotherapy: Concurrent Uses, Efficacy and Impact on Prognosis. Nova Science Publishers, Incorporated, 2017.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Rathore, Ritesh. Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers. INTECH Open Access Publisher, 2012.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Glynne-Jones, Rob, Mark Harrison, and David Sebag-Montefiore. Rectal cancer. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199696567.003.0007.

Повний текст джерела
Анотація:
Chapter 7 assesses the role of radiation therapy in rectal cancer, with emphasis on preoperative imaging, patient selection for preoperative chemoradiotherapy (CRT) and short-course preoperative radiotherapy (SCPRT), and postoperative chemoradiation. We describe the various available planning techniques. More conformal techniques such as intensity-modulated radiotherapy (IMRT), volume-modulated arc therapy (VMAT), and brachytherapy are also described. In addition, chemoradiation and radiotherapy as an adjunct to local excision and endoluminal irradiation are also reviewed.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Radiosensitizers and Radiochemotherapy in the Treatment of Cancer. Taylor & Francis Group, 2014.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Lehnert, Shirley. Radiosensitizers and Radiochemotherapy in the Treatment of Cancer. Taylor & Francis Group, 2015.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lehnert, Shirley. Radiosensitizers and Radiochemotherapy in the Treatment of Cancer. Taylor & Francis Group, 2019.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Lehnert, Shirley. Radiosensitizers and Radiochemotherapy in the Treatment of Cancer. Taylor & Francis Group, 2014.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Lehnert, Shirley. Radiosensitizers and Radiochemotherapy in the Treatment of Cancer. Taylor & Francis Group, 2014.

Знайти повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Частини книг з теми "Chemoradiotheraoy"

1

Verheij, Marcel, and Harry Bartelink. "Chemoradiotherapy." In Encyclopedia of Cancer, 1–7. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-642-27841-9_1074-3.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Weiss, Christian, and Claus Rödel. "Chemoradiotherapy." In Management of Bladder Cancer, 361–77. New York, NY: Springer New York, 2014. http://dx.doi.org/10.1007/978-1-4939-1881-2_28.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Verheij, Marcel, and Harry Bartelink. "Chemoradiotherapy." In Encyclopedia of Cancer, 947–53. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-46875-3_1074.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Adelstein, David J. "Concurrent Chemoradiotherapy." In Squamous Cell Head and Neck Cancer, 187–95. Totowa, NJ: Humana Press, 2005. http://dx.doi.org/10.1007/978-1-59259-938-7_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Wong, Gordon, and Minesh P. Mehta. "Combined Chemoradiotherapy Advances." In Cancer Treatment and Research, 277–301. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-36744-6_13.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Kato, Ken. "Chemotherapy and Chemoradiotherapy." In Esophageal Squamous Cell Carcinoma, 197–225. Tokyo: Springer Japan, 2014. http://dx.doi.org/10.1007/978-4-431-54977-2_12.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Kato, Ken. "Chemotherapy and Chemoradiotherapy." In Esophageal Squamous Cell Carcinoma, 253–82. Singapore: Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-4190-2_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Ni, Xingchu, and Kun Huang. "Radiotherapy and Chemoradiotherapy." In Gastric Cardiac Cancer, 283–97. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-79114-2_15.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Fietkau, Rainer, and Sabine Semrau. "Stage III: Definitive Chemoradiotherapy." In Frontiers of Radiation Therapy and Oncology, 122–34. Basel: KARGER, 2009. http://dx.doi.org/10.1159/000262467.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Wallach, Jonathan B., and Michael J. Nissenblatt. "Chemoradiotherapy for Gastrointestinal Malignancies." In Geriatric Gastroenterology, 1991–2003. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-30192-7_102.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Тези доповідей конференцій з теми "Chemoradiotheraoy"

1

Sudakov, A. I., E. P. Kulikov, S. A. Mertsalov, A. A. Nikiforov, and V. A. Grigorenko. "GENETIC POLYMORPHISM AND COLORECTAL CANCER." In NOVEL TECHNOLOGIES IN MEDICINE, BIOLOGY, PHARMACOLOGY AND ECOLOGY. Institute of information technology, 2022. http://dx.doi.org/10.47501/978-5-6044060-2-1.105-109.

Повний текст джерела
Анотація:
The article analyzes the relationship of polymorphism of a number of genes with some features of colorectal cancer, such as the aggressiveness of its course and development of the disease, the effectiveness of preoperative chemoradiotherapy. The data obtained can be used to deter-mine individual tactics for treating patients.
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Im, Keon-Il, Young-Sun Nam, Nayoun Kim, YuneJin Song, Young-Woo Jeon, Jung-Yeon Lim, and Seok-Goo Cho. "Abstract 465: Regulation of HMGB1 release protects chemoradiotherapy-associated mucositis." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-465.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

Flebbe, H., M. Spitzner, PE Marquet, E. Hessmann, BM Ghadimi, A. König, and M. Grade. "Inhibition of STAT-3 sensitizes pancreatic cancer cells to chemoradiotherapy." In Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733563.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Pethe, W., S. Drüg-Skamel, and J. Langer. "Hearing after induction chemotherapy and definitive chemoradiotherapy in advanced oropharyngeal carcinoma." In Abstract- und Posterband – 89. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Forschung heute – Zukunft morgen. Georg Thieme Verlag KG, 2018. http://dx.doi.org/10.1055/s-0038-1640119.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Naito, Yoshiki, Masamichi Nakayama, Hiroto Ishikawa, Kenjiro Takahashi, Toru Hisaka, Koji Okuda, Masaru Fukahori, et al. "Abstract 4762: Clinicopathologic findings of borderline resectable pancreatic cancer after neoadjuvant chemoradiotherapy." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4762.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Gaedcke, Jochen, Marian Grade, Klaus Jung, Hendrik A. Wolff, Tim Beissbarth, Heinz Becker, Thomas Ried, and Michael Ghadimi. "Abstract 5640: KRAS and BRAF in rectal cancer treated with preoperative chemoradiotherapy." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5640.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Tahir, Bilal, and Marten Dooper. "Radiation dose on oesophagus predicts OS in SCLC patients treated with chemoradiotherapy." In European Lung Cancer Congress 2022, edited by Stefan Rauh. Baarn, the Netherlands: Medicom Medical Publishers, 2022. http://dx.doi.org/10.55788/38c2928d.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Kaneko, Kensuke. "Abstract 863: Clinical significance of mucinous production in rectal cancer after preoperative chemoradiotherapy." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-863.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Warren, Graham W., Marcus Randall, Ronald McGarry, Mahesh Kudrimoti, and Vivek Rangnekar. "Abstract 1408: Nicotine decreases the therapeutic efficacy of radiotherapy and chemoradiotherapy in vivo." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-1408.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Perera, Jananie, and Gemma Eminowicz. "479 Retrospective review of hematological toxicity of chemoradiotherapy in locally advanced cervical cancers." In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.38.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.

Звіти організацій з теми "Chemoradiotheraoy"

1

Liu, Haonan, Xiaobing Qin, and Zhengxiang Han. Concurrent chemoradiotherapy followed by adjuvant chemotherapy versus concurrent chemoradiotherapy alone in locally advanced cervical cancer: a systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2022. http://dx.doi.org/10.37766/inplasy2022.9.0089.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
2

Chen, Jiuzhou, Yaru Guo, Yan Yuan, Miao Fan, and Yong Xin. Neoadjuvant chemoradiotherapy for resectable gastric cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, March 2022. http://dx.doi.org/10.37766/inplasy2022.3.0164.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
3

wang, hesong, chunyang song, wenzhao deng, xiaohan zhao, and wenbin shen. Evaluation of Neoadjuvant Immune Combined Therapy and Traditional Neoadjuvant Therapy for Resectable Esophageal Cancer: A Systematic Review and Single-arm and Network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2022. http://dx.doi.org/10.37766/inplasy2022.12.0060.

Повний текст джерела
Анотація:
Review question / Objective: Population: Patients with histologically-confirmed resectable esophageal carcinoma; Intervention: Neoadjuvant immunotherapy combined with chemotherapy or neoadjuvant immunotherapy combined with chemoradiotherapy followed by surgery; Control: Neoadjuvant chemotherapy or neoadjuvant chemoradiotherapy followed by surgery; Outcomes: Treatment related adverse events, r0 resection rate, pathological complete response, major pathological response, objective response rate, disease control rate, postoperative complications, postoperative mortality, 1/2/3/5year overall survival, 1/2/3/5year disease free survival; Study Design: All prospective and restrospective studies.
Стилі APA, Harvard, Vancouver, ISO та ін.
4

Song, Jiating, Qi Chen, Lele Jian, Qihua Huang, and hang Du. Preventive effects of different mouthwashes on oral mucositis associated with radiotherapy and chemotherapy: a network Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, May 2022. http://dx.doi.org/10.37766/inplasy2022.5.0061.

Повний текст джерела
Анотація:
Review question / Objective: By using mesh meta-analysis, we can determine the most effective mouthwash during clinical care for patients with chemoradiotherapy-associated oral mucositis. Condition being studied: At present, we have carried out a preliminary literature search for the identification of search terms and search formulas. Eligibility criteria: Study type - RCT; study subjects: chemoradiotherapy patients with potential risk of OM, no OM before the study, unlimited age, nationality and duration; intervention: oral care liquid gargle; outcome index: incidence of OM.
Стилі APA, Harvard, Vancouver, ISO та ін.
5

Lu, Xinyu, Yaxu Su, Yong Xin, and Yufei Lou. Survival and complications after neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for esophageal adenocarcinoma: A meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, November 2022. http://dx.doi.org/10.37766/inplasy2022.11.0112.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
6

Guo, Yaru, Mingna Xu, and Yong Xin. Survival and complications after Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for Esophageal Squamous Cell Cancer：a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, December 2021. http://dx.doi.org/10.37766/inplasy2021.12.0031.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
7

Lu, Jiaying, Na Li, Ji Ma, Nan Yao, and Yuanhu Yao. High-dose versus standard-dose radiotherapy in concurrent chemoradiotherapy for inoperable esophageal cancer: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, October 2022. http://dx.doi.org/10.37766/inplasy2022.10.0045.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
8

Miao, Yu, Deng-Chao Wang, Sheng Li, Li-Yan Huang, Jian Wei, and Yue-Hua Lei. Efficacy and safety of preoperative radiotherapy versus chemoradiotherapy in advanced rectal cancer: A randomized controlled meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, September 2021. http://dx.doi.org/10.37766/inplasy2021.9.0035.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
9

Yuan, Yan, Yaru Guo, Jiuzhou Chen, Miao Fang, and Yong Xin. Nimotuzumab combined with chemoradiotherapy for the treatment of cervical cancer: A meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2022. http://dx.doi.org/10.37766/inplasy2022.4.0098.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
10

Guo, Yaru, Mingna Xu, and Miao Fang. The efficacy and safety of Recombinant human adenovirus-p53 for cervical cancer radiotherapy and chemoradiotherapy: a Meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, April 2021. http://dx.doi.org/10.37766/inplasy2021.4.0014.

Повний текст джерела
Стилі APA, Harvard, Vancouver, ISO та ін.
Також вас можуть зацікавити розширені добірки на тему "Chemoradiotheraoy" для конкретних типів джерел:
Статті в журналах Дисертації
Ми пропонуємо знижки на всі преміум-плани для авторів, чиї праці увійшли до тематичних добірок літератури. Зв'яжіться з нами, щоб отримати унікальний промокод!

До бібліографії